Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Conditions
- Interventions
- Drug: SunitinibDrug: Trastuzumab and PertuzumabDrug: Vemurafenib and CobimetinibDrug: PalbociclibDrug: Nivolumab and IpilimumabDrug: AbemaciclibDrug: Atezolizumab and PHESGODrug: Atezolizumab and TalazoparibDrug: Tucatinib plus Trastuzumab Subcutaneous (SC)Drug: FutibatinibDrug: TalazoparibDrug: TemsirolimusDrug: RegorafenibDrug: OlaparibDrug: PembrolizumabDrug: EntrectinibDrug: Larotrectinib
- First Posted Date
- 2016-02-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- American Society of Clinical Oncology
- Target Recruit Count
- 3791
- Registration Number
- NCT02693535
- Locations
- 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States
🇺🇸Sutter Auburn, Auburn, California, United States
Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2022-06-15
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02691793
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2016-02-25
- Target Recruit Count
- 300
- Registration Number
- NCT02688491
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2021-11-29
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 226
- Registration Number
- NCT02689167
- Locations
- 🇫🇷
CHU Besancon, Besancon, Franche-Comté, France
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 886
- Registration Number
- NCT02684006
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Tower Hematology Oncology Medical Group, Beverly Hills, California, United States
A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- vghtpe user
- Target Recruit Count
- 13
- Registration Number
- NCT02626754
- Locations
- 🇨🇳
Taipei Vterans General Hospital, Taipei, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
🇨🇳Chang Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT02623127
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 4
- Registration Number
- NCT02560012
- Locations
- 🇺🇸
UTHealth Memorial Hermann Cancer Center, Houston, Texas, United States
Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Institut Claudius Regaud
- Target Recruit Count
- 47
- Registration Number
- NCT02555748
- Locations
- 🇫🇷
CHU DE BORDEAUX - Hôpital Saint-André, Bordeaux, France
🇫🇷Institut Claudius Regaud, Toulouse, France
🇫🇷CHU DE LIMOGES - Hôpital Dupuytren, Limoges, France
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT02483247
- Locations
- 🇺🇸
Indiana University Health Goshen, Goshen, Indiana, United States
🇺🇸Louisiana State Univesity, New Orleans, Louisiana, United States
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.